These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27730846)

  • 1. Compounds and methods for inhibiting histone demethylases: a patent evaluation of US20160102096A1.
    Thaler F; Mercurio C
    Expert Opin Ther Pat; 2016 Dec; 26(12):1367-1370. PubMed ID: 27730846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
    Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Diallo H; Douault C; Drewes G; Eagle R; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Liddle J; Mosley J; Muelbaier M; Randle R; Rioja I; Rueger A; Seal GA; Sheppard RJ; Singh O; Taylor J; Thomas P; Thomson D; Wilson DM; Lee K; Prinjha RK
    J Med Chem; 2016 Feb; 59(4):1357-69. PubMed ID: 26771107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
    Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Drewes G; Eagle R; Garton N; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Pemberton M; Rioja I; Seal GA; Shipley T; Singh O; Suckling CJ; Taylor J; Thomas P; Wilson DM; Lee K; Prinjha RK
    J Med Chem; 2016 Feb; 59(4):1370-87. PubMed ID: 26771203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases.
    Luo X; Liu Y; Kubicek S; Myllyharju J; Tumber A; Ng S; Che KH; Podoll J; Heightman TD; Oppermann U; Schreiber SL; Wang X
    J Am Chem Soc; 2011 Jun; 133(24):9451-6. PubMed ID: 21585201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
    Rotili D; Tomassi S; Conte M; Benedetti R; Tortorici M; Ciossani G; Valente S; Marrocco B; Labella D; Novellino E; Mattevi A; Altucci L; Tumber A; Yapp C; King ON; Hopkinson RJ; Kawamura A; Schofield CJ; Mai A
    J Med Chem; 2014 Jan; 57(1):42-55. PubMed ID: 24325601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future therapeutic potential of histone demethylases: A critical analysis.
    Natoli G; Testa G; De Santa F
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):607-15. PubMed ID: 19736620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme kinetic studies of histone demethylases KDM4C and KDM6A: towards understanding selectivity of inhibitors targeting oncogenic histone demethylases.
    Kristensen JB; Nielsen AL; Jørgensen L; Kristensen LH; Helgstrand C; Juknaite L; Kristensen JL; Kastrup JS; Clausen RP; Olsen L; Gajhede M
    FEBS Lett; 2011 Jun; 585(12):1951-6. PubMed ID: 21575637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
    Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
    FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting histone lysine demethylases by truncating the histone 3 tail to obtain selective substrate-based inhibitors.
    Lohse B; Nielsen AL; Kristensen JB; Helgstrand C; Cloos PA; Olsen L; Gajhede M; Clausen RP; Kristensen JL
    Angew Chem Int Ed Engl; 2011 Sep; 50(39):9100-3. PubMed ID: 21919140
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibiting the Jumonji family: a potential new clinical approach to targeting aberrant epigenetic mechanisms.
    Martinez ED; Gazdar AF
    Epigenomics; 2016 Mar; 8(3):313-6. PubMed ID: 26918824
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).
    Leurs U; Clausen RP; Kristensen JL; Lohse B
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5811-3. PubMed ID: 22917519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.
    Chin YW; Han SY
    Expert Opin Ther Pat; 2015 Feb; 25(2):135-44. PubMed ID: 25468267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substrate- and cofactor-independent inhibition of histone demethylase KDM4C.
    Leurs U; Lohse B; Rand KD; Ming S; Riise ES; Cole PA; Kristensen JL; Clausen RP
    ACS Chem Biol; 2014 Sep; 9(9):2131-8. PubMed ID: 25014588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enabling lead discovery for histone lysine demethylases by high-throughput RapidFire mass spectrometry.
    Hutchinson SE; Leveridge MV; Heathcote ML; Francis P; Williams L; Gee M; Munoz-Muriedas J; Leavens B; Shillings A; Jones E; Homes P; Baddeley S; Chung CW; Bridges A; Argyrou A
    J Biomol Screen; 2012 Jan; 17(1):39-48. PubMed ID: 21859681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput TR-FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylases.
    Yu V; Fisch T; Long AM; Tang J; Lee JH; Hierl M; Chen H; Yakowec P; Schwandner R; Emkey R
    J Biomol Screen; 2012 Jan; 17(1):27-38. PubMed ID: 21859682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The KDM5 family of histone demethylases as targets in oncology drug discovery.
    Rasmussen PB; Staller P
    Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysine demethylases inhibitors.
    Suzuki T; Miyata N
    J Med Chem; 2011 Dec; 54(24):8236-50. PubMed ID: 21955276
    [No Abstract]   [Full Text] [Related]  

  • 18. KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemia.
    Boila LD; Chatterjee SS; Banerjee D; Sengupta A
    Exp Hematol; 2018 Feb; 58():44-51.e7. PubMed ID: 29111428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
    Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
    J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new horizon for epigenetic medicine?
    Chen S; Shi Y
    Cell Res; 2013 Mar; 23(3):326-8. PubMed ID: 22986503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.